Boiron: HAS confirms unfavourable ruling
(CercleFinance.com) - Boiron has said that the committee of transparency of the high health Authority (HAS) maintains its opinion against the reimbursement of homeopathic drugs, an opinion that was delivered in record time, and which does not take into account the specificity of these medicines.
In Boiron's opinion, in its methodology the commission has not incorporated the health benefits of these medicinal products for the public, the absence of therapeutic indications resulting from their regulatory status and the individualised nature of homeopathic treatment.
The final decision now lies with the government, Boiron adds, stressing that 60% of its turnover would be directly impacted by a change in the reimbursement rate of homeopathic medicines.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In Boiron's opinion, in its methodology the commission has not incorporated the health benefits of these medicinal products for the public, the absence of therapeutic indications resulting from their regulatory status and the individualised nature of homeopathic treatment.
The final decision now lies with the government, Boiron adds, stressing that 60% of its turnover would be directly impacted by a change in the reimbursement rate of homeopathic medicines.
Copyright (c) 2019 CercleFinance.com. All rights reserved.